TRVI
Trevi Therapeutics Inc
NASDAQ: TRVI · HEALTHCARE · BIOTECHNOLOGY
$18.09
-1.84% today
Updated 2026-07-29
Market cap
$2.38B
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-0.28
Dividend yield
—
52W range
$7 – $20
Volume
2.2M
WallStSmart proprietary scores
25
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C8.5
Quality
A3.0
Profitability
D5.0
Valuation
C+3/9
Piotroski F-Score
Weak
8.8
Altman Z-Score
Safe zone
—
Industry rank
—
View all highly rated stocks (75+) →206 stocks currently score above 75
Price targets
Analyst target
$24.90
+37.65%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
2 Strong Buy8 Buy0 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Altman Z 8.80 — safe zone
+ Debt/equity 0.00x — low leverage
Risks
- Piotroski 3/9 — weak financial health
- Thin margins at 0.00%
- Negative free cash flow $-16.79M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | $-29.15M | $-29.07M | $-47.91M | $-42.76M | $-13.19M |
| EPS | — | — | — | — | $-0.28 |
| Free cash flow | $-28.33M | $-31.85M | $-38.29M | $-42.10M | $-16.79M |
| Profit margin | — | — | — | — | — |
Peer comparison
Smart narrative
Trevi Therapeutics Inc trades at $18.09. Our Smart Value Score of 25/100 indicates the stock is weak. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of 8.80, it sits in the safe zone.
Frequently asked questions
What is Trevi Therapeutics Inc's stock price?
Trevi Therapeutics Inc (TRVI) trades at $18.09.
Is Trevi Therapeutics Inc overvalued?
Trevi Therapeutics Inc carries a Smart Value Score of 25/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Trevi Therapeutics Inc (TRVI)?
The 12-month analyst consensus target is $24.90, about 37.6% above the current $18.09. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
Altman Z-Score?
Trevi Therapeutics Inc's Altman Z-Score is 8.80, which places it in the safe zone. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio—
ROE-26.50%
Beta1.00
50D MA$15.72
200D MA$12.75
Shares out0.14B
Float0.12B
Short ratio—
Avg volume2.2M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—